An Fc-Competent Anti-Human TIGIT Blocking Antibody Ociperlimab (BGB-A1217) Elicits Strong Immune Responses and Potent Anti-Tumor Efficacy in Pre-Clinical Models.

导出 LinkOut

翻译打印收藏纠错

作者： Xin,Chen ^[1] ; Liu,Xue ^[2] ; Xiao,Ding ^[3] ; Jing,Zhang ^[2] ; Lei,Jiang ^[1] ; Sha,Liu ^[1] ; Hongjia,Hou ^[1] ; Bin,Jiang ^[3] ; Liang,Cheng ^[2] ; Qing,Zhu ^[2] ; Lijie,Zhang ^[3] ; Xiaosui,Zhou ^[1] ; Jie,Ma ^[2] ; Qi,Liu ^[2] ; Yucheng,Li ^[2] ; Zhiying,Ren ^[2] ; Beibei,Jiang ^[1] ; Xiaomin,Song ^[1] ; Jing,Song ^[2] ; Wei,Jin ^[3] ; Min,Wei ^[2] ; Zhirong,Shen ^[3] ; Xuesong,Liu ^[1] ; Lai,Wang ^[1] ; Kang,Li ^[2] ; Tong,Zhang ^[1]

作者单位： Department of Biology, BeiGene (Beijing) Co., Ltd., Beijing, China. ^[1] Department of Biologics, BeiGene (Beijing) Co., Ltd., Beijing, China. ^[2] Department of Discovery Biomarkers, BeiGene (Beijing) Co., Ltd., Beijing, China. ^[3]

关键词 BGB-A1217 Fc effector function TIGIT antibody cancer immunotherapy immune checkpoint ociperlimab

主题词动物(Animals);抗体, 单克隆(Antibodies, Monoclonal);免疫(Immunity);配体(Ligands);小鼠(Mice);肿瘤(Neoplasms);受体, 免疫(Receptors, Immunologic)

DOI 10.3389/fimmu.2022.828319

PMID 35273608

发布时间 2022-05-02

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交